Form 4: Enliven Therapeutics Director Richard A. Heyman Sells Shares Under 10b5-1 Trading Plan

Director Richard A. Heyman of Enliven Therapeutics, Inc. sold 1,270 shares of common stock at a weighted average price of $21.4787, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard A. Heyman, a director of Enliven Therapeutics, Inc., reported the sale of 1,270 shares of common stock on June 17, 2024.
• The sale was executed at a weighted average price of $21.4787 per share, with individual prices ranging from $21.22 to $22.0783.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on July 17, 2023.
• Following the transaction, Heyman directly owns 134,615 shares and indirectly owns 37,407 shares through the Richard A. Heyman and Anne E. Daigle Trust and 28,567 shares through RAHD Capital LLC.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares under a pre-existing trading plan.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned to avoid accusations of trading on inside information. The use of a 10b5-1 plan suggests the director's sales were planned well in advance.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates